Clinical experience with sodium-glucose transport 2 (SGLT2) inhibitors in patients with systemic lupus erythematosus.

Int Urol Nephrol · 2026 · PMC13121182 · PMID 41102434

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The use of SGLT2is in 9 SLE patients with DM [ 6 ], CKD [ 7 ], and cardiac disease [ 3 ] showed a trend of reduction in proteinuria, stable kidney function over-time, and without adverse cardiovascular events despite a high-risk population.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.